Novartis to Acquire Regulus Therapeutics for Up to $1.7 Billion
Swiss pharmaceutical giant Novartis (NYSE: NVS) is set to acquire U.S.-based Regulus Therapeutics Inc. (NASDAQ:...
CSPC’s JMT202 Receives FDA IND Approval for Hypertriglyceridemia Trials
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has secured an investigational new drug (IND) approval...
Guilin Sanjin’s BC006 Monoclonal Antibody Gains NMPA Approval for IPF Trials
Guilin Sanjin Pharmaceutical Co., Ltd. (SHE: 002275) announced that its Shanghai-based subsidiary Dragon Boat Biopharmaceutical’s...
Innovent Biologics Presents Positive IBI302 Results for nAMD at ARVO 2025
China-based Innovent Biologics, Inc. (HKG: 1801) announced the presentation of 1-year results from its Phase...
AccurEdit Therapeutics’ ART001 Shows Promising Results in ATTR Treatment
China-based gene editing therapy specialist AccurEdit Therapeutics (Suzhou) Co., Ltd. has published the latest data...
Novo Nordisk’s Once-Daily Wegovy NDA Accepted for FDA Review
Denmark-based Novo Nordisk (NYSE: NVO) announced that its New Drug Application (NDA) filing for its...
Nanjing Perlove Medical Equipment Files IPO Application in Hong Kong
China-based Nanjing Perlove Medical Equipment Co., Ltd., a specialist in medical imaging and surgical robotics,...
Sanofi’s Opella Becomes Independent Consumer Healthcare Company After CD&R Deal
Opella, the consumer health business of French pharmaceutical giant Sanofi (NASDAQ: SNY), became an independent...
Johnson & Johnson’s Imaavy Gains FDA Approval for Generalized Myasthenia Gravis
US giant Johnson & Johnson (J&J, NYSE: JNJ) unveiled a market approval in the United...
Chengdu Origen Announces First Patient Dosing of KH658 in Wet AMD Trial
China-based Chengdu Origen Biotechnology Co., Ltd. announced the first patient dosing of KH658, a gene...
China’s 13 Ministries Release Guidance to Optimize Primary Healthcare Institutions
The National Health Commission, National Development and Reform Commission, and State Commission Office of Public...
AstraZeneca’s Breztri Aerosphere Meets Primary Endpoints in Phase III Asthma Trials
UK-based pharmaceutical firm AstraZeneca (AZ; NASDAQ: AZN) this week unveiled results from the Phase III...
Eli Lilly Reports 45% YOY Sales Growth in Q1 2025, Driven by Mounjaro and Zepbound
US-based Eli Lilly & Co. (NYSE: LLY) released its Q1 2025 financial report, revealing sales...
Eucerin Partners with Guangzhou United Family Hospital for Dermatology Services
Eucerin, the dermatology unit of Germany-based skincare firm Beiersdorf AG, has entered into a partnership...
Alphamab and CSPC Announce Positive Interim Results for KN026 in HER2+ Gastric Cancer Trial
China-based firms Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) announced the...
Innovent Biologics Initiates First-in-Human Dosing of IBI3020 in Phase I Trial
China-based Innovent Biologics, Inc. (HKG: 1801) announced the first-in-human dosing of IBI3020, a first-in-class CEACAM5-targeted...
Dizal Pharmaceutical Reports Strong Revenue Growth in 2024 and Q1 2025
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) released its 2024 financial report, alongside its Q1...
Ipsen and Shanghai Pharmaceutical Partner to Expand Diphereline Coverage in China
France-based Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced the signing of a cooperation agreement with...
Novartis Q1 2025 Results: Net Sales Up 15% YOY, Strong Growth in Key Brands
Swiss pharmaceutical giant Novartis (NYSE: NVS) released its Q1 2025 financial report, showing net sales...
Merck Sharp & Dohme Announces $1 Billion Biologics Center in Wilmington, Delaware
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has announced the establishment of...